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Abstract
Genetic susceptibility to colorectal cancer is caused by rare pathogenic mutations and common 
genetic variants that contribute to familial risk. Here we report the results of a two-stage 
association study with 18,299 cases of colorectal cancer and 19,656 controls, with follow-up of the 
most statistically significant genetic loci in 4,725 cases and 9,969 controls from two Asian 
consortia. We describe six new susceptibility loci reaching a genome-wide threshold of 
P<5.0E-08. These findings provide additional insight into the underlying biological mechanisms 
of colorectal cancer and demonstrate the scientific value of large consortia-based genetic 
epidemiology studies.
Introduction
The estimated lifetime risk of colorectal cancer (CRC) is 5.2% for men and 4.8% for women 
in the United States1. The narrow-sense heritability estimates based on twin and family 
studies of CRC range from 12 to 35%2,3. Although several genome-wide association studies 
(GWAS) of CRC have successfully identified common single-nucleotide polymorphisms 
(SNPs) associated with CRC risk4–21, a large fraction of the heritability still remains 
elusive22. Our GWAS combines data from four large CRC consortia, the Colorectal Cancer 
Transdisciplinary (CORECT) Study, the Colon Cancer Family Registry (CFR), the 
Molecular Epidemiology of Colorectal Cancer (MECC) Study and the Genetics and 
Epidemiology of Colorectal Cancer Consortium (GECCO) to elucidate previously 
undiscovered susceptibility loci for CRC. The current meta-analysis identifies novel 
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genome-wide significant risk regions at 3p14.1, 3p22.1, 10q24.2, 12q24.12, 12q24.22 and 
20q13.13.
Results
Study Populations and Population Stratification
Data for this discovery analysis focuses on individuals of the European ancestral heritage 
from North America, Australia and Europe. Our discovery analysis includes 19 
observational studies genotyped with high-density SNP arrays and imputed to the 1,000 
Genomes Project March 2012 reference panel23,24 (Supplementary Table 1). We employ an 
inverse-variance-weighted fixed effects meta-analysis of study-specific logistic regression 
results after filtering data for quality control (QC). Quantile-quantile plots show no 
appreciable evidence of population stratification for the meta-analysis (Supplementary Fig. 
1) or by the individual discovery studies (Supplementary Fig. 2) before and after adjustment 
for principal components (PCs), and the sample size-corrected marginal lambda (equivalent 
to 1,000 cases and 1,000 controls) measures 1.003 in the discovery meta-analysis. The PC 
plots for ancestry indicate no difference between cases and controls in the respective 
discovery GWAS studies (Supplementary Fig. 3).
Confirmation of Prior Studies and Discovery
We evaluate the quality and effectiveness of our study design and analytic methods by 
assessing previously reported CRC susceptibility loci. We replicate the results for 41 of the 
47 (P<0.05, unadjusted for multiple testing) published autosomal susceptibility variants for 
CRC (Supplementary Table 2). We turn our attention to the discovery of new susceptibility 
loci (Supplementary Fig. 4) by investigating the top 200 independent loci detected in the 
European discovery phase (Supplementary Table 3) in two separate East Asian consortia. 
Overall, our combined meta-analysis across European and Asian studies discovers six new 
susceptibility loci reaching a statistical threshold of P<5.0E-08: at chromosome 3p22.1 
(rs35360328), 3p14.1 (rs812481), 10q24.2 (rs11190164), 12q24.12 (rs7137828), 12q24.22 
(rs73208120), and 20q13.13 (rs6066825; Table 1; Supplementary Table 4). The odds ratios 
(ORs) across these six loci indicate a range of a 9% to 16% increase in the odds of 
developing CRC per risk allele, similar to previously reported CRC susceptibility loci. A 
seventh susceptibility locus tagged by rs4946260 at 6q22.1 approaches genome-wide 
significance (P=6.27E-08). The ORs are consistent across populations and genotyping 
platforms as shown by chi-square tests for heterogeneity, with only one locus showing 
marginally significant heterogeneity (rs6066825/20q13.13, Phet=0.04).
Replication in Asian Populations
Forest plots for the six genome-wide significant loci show that the risk alleles identified in 
European populations replicate broadly across the Asian populations even though allele 
frequencies differ substantially (Fig. 1). Two SNPs were not available for replication in the 
Asian studies because they are rare in Asians.
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Genomic Location and Candidate Genes
Several of the six susceptibility SNPs fall within regions harboring genes known to be 
involved in the pathogenesis of CRC (Supplementary Fig. 5). Rs35360328 and a 
corresponding tagSNP at 3p22.1 (rs35364139, r2=0.8, P=1.7E-07) lie in an intergenic region 
within ~300 kb of CTNNB1, the gene that encodes β-catenin. β-Catenin is a key member of 
the WNT signaling pathway and is commonly mutated in CRC development25,26. There are 
no histone marks in the vicinity of either rs35360328 or rs35364139 in any colon-derived 
cells in the publicly available ENCODE chromatin immunoprecipitation (ChIP)-seq tracks, 
making these unlikely to be the functional SNPs in this region (Supplementary Fig. 5). 
However, there are 26 other SNPs in linkage disequilibrium (LD) with rs35364139 (r2>0.5, 
CEU population), which may disrupt biofeatures or regulatory elements resulting in the 
observed CRC risk. Together, the physical proximity of this newly identified susceptibility 
locus, relevant functional biology and adjacent regulatory marks suggest that CTNNB1 is an 
intriguing candidate target gene of a putative enhancer.
The second locus on chromosome 3 is located at 3p14.1 (rs812481) and is intronic of 
LRIG1, a gene encoding a transmembrane protein that interacts with epidermal growth 
factor receptor-family tyrosine kinase family members27–29. LRIG1 has recently been 
described as a marker of quiescent colon crypt stem cells activated to proliferate following 
injury30. No histone marks are found in the vicinity of rs812481, making it unlikely to be the 
functional SNP. Notably, rs3856595 (P=2.4E-07), in LD (r2>0.5, CEU population) with 
rs812481, is located in a LRIG1 intronic active enhancer peak (H3K27ac4) in sigmoid colon 
epithelium. A second SNP in LD with rs812481 is rs231276 (P=2.0E-06), which resides in 
an H3K4me1 enhancer peak in a CRC cell (HCT-116). This peak is intronic of SLC25A26, 
a mitochondrial transport protein.
The SNP at 10q24.2 (rs11190164) lies in a genomic region containing multiple genes 
including SLC25A28, ENTPD7, COX15, CUTC and ABCC2. Several SNPs in high LD 
with rs11190164 map to putative enhancers, promoters or 3′ UTRs of genes within the 
region. A recent study identified rs1035209, 6.3 kb upstream from rs11190164 (CEU 
r2=0.4), to be significantly associated with CRC risk17. In addition, rs3740078 (distance to 
rs11190614=93,887 bp, r2=0.71, CEU population; P=3.2E-05) causes a synonymous change 
in the coding sequence of ENTPD7. While ENTPD7 has been linked to intestinal epithelial 
inflammation in mice and is expressed in normal colonic epithelium31, a role in CRC has not 
been previously reported.
Rs3184504 at 12q24.12 implicates SH2B3 as a putative target gene for CRC susceptibility. 
SH2B3 is an adaptor protein involved in cytokine signaling and functions as a classic tumor 
suppressor gene in B-precursor acute lymphoblastic leukemia that increases STAT3 
phosphorylation32. Less is known about its signaling roles in the colon, but rs3184504 is a 
missense variant (Trp262Arg) that is a known risk allele for celiac disease and other 
immune-related disorders33 and is a well-established risk factor for type 1 diabetes34 and 
hypertension35. Several other SNPs in LD with rs3184504 also map to putative regulatory 
regions, but further work is needed to functionally characterize this missense variant or these 
other SNPs. Other genes within this region, including CUX2, BRAP and ACAD10 are also 
potential candidate genes.
Schumacher et al. Page 3
Nat Commun. Author manuscript; available in PMC 2016 July 30.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The SNP at 12q24.22 (rs73208120) is independent of rs3184504 at 12q24.12 (r2=0.002, 
CEU population) and lies intronic of NOS1. NOS1 encodes neuronal nitric oxide synthase 1 
that generates nitric oxide a reactive free radical involved in several biologic processes, 
including inflammation, infection and antimicrobial and antitumoral activities36. There are 
several SNPs in LD with rs73208120, but none map to the candidate enhancer regions.
The SNP at 20q13.13 (rs6066825) lies within an intron of the PREX1 gene that encodes the 
Rac-guanine nucleotide exchange factor P-Rex1, a signaling protein involved in cell 
migration and invasion in some cell types37. There are 35 SNPs in LD with rs6066825 
(r2>0.5, CEU population), all intronic or immediately downstream of PREX1. The most 
promising functional candidates are three SNPs, rs2092492 (r2=0.62, CEU population), 
rs6066823 (r2=0.62, CEU population), and rs6066825 itself that lie within a putative active 
enhancer marked by an H3K27ac ChIP-seq peak in sigmoid colon tissue.
Discussion
In conclusion, the combined meta-analysis of 52,649 individuals facilitated the discovery of 
six new susceptibility loci for CRC. Additional CRC loci remain to be discovered despite the 
large sample sizes included in our discovery meta-analysis. Although replication of 
suggestive loci from the discovery phase in similar ancestral populations would be more 
powerful due to LD and effect allele frequency differences, this study identified six novel 
CRC risk loci. This study identified opportunities to explore new biologic mechanisms for 
predisposition to CRC and the potential for translation into improved risk prediction for 
populations of diverse ancestral heritage.
Methods
Our initial GWAS combined data from three large CRC consortia, the CORECT Study, the 
CFR, the MECC and the GECCO to elucidate previously undiscovered susceptibility loci for 
CRC. Data for this discovery analysis focused on individuals of European ancestral heritage 
from North America, Australia and Europe. Detailed methods are described in the 
Supplementary Methods. In brief, samples from 19 observational studies genotyped with 
high-density SNP arrays and imputed to the 1,000 Genomes Project March 2012 reference 
panel24 contributed to the discovery meta-analysis. Replication of the top 200 independent 
SNPs was performed in two additional consortium studies from Asian populations. The 
studies included in the discovery and replication phases are listed in Supplementary Table 1.
Discovery phase genotyping and QC
The details on study design and characteristics for each study and substudy in the discovery 
phase are provided in the Supplementary Methods. In brief, the discovery phase consisted of 
four CRC consortia. The CORECT consortium coordinated genotyping and analysis of six 
observational studies of CRC for the present analysis: (1) MECC2, (2) CFR2, (3) Kentucky 
case-control study, (4) American Cancer Society CPS II nested case-control study, (5) 
Melbourne nested case-control study and (6) Newfoundland case-control study. Genotyping 
as part of CORECT was conducted using a custom Affymetrix genome-wide platform (the 
Axiom CORECT Set) with ~1.3 million SNPs and insertions and deletions (indels) on two 
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physical genotyping chips (pegs). In the MECC1 study, germline DNA was extracted from 
peripheral blood samples and genotyped in two batches using the Illumina HumanOmni 
2.5–8 BeadChip, which measures nearly 2.4 million SNPs and indels. Batch 1 (414 cases and 
155 controls) was run at the Case Western Reserve University and batch 2 (104 cases and 
376 controls) was run at the University of Michigan. Germline DNA for the CFR1 study was 
extracted from peripheral blood samples and genotyped in two batches using three different 
platforms – the Illumina Human1M or Human1M-Duo (CFR1-Set1) and the Illumina 
HumanOmni1-Quad (CFR1-Set 2) – each containing ~1.2 million SNPs and indels. 
Genotype data were cleaned based on QC metrics at the individual subject and SNP levels. 
Samples with <95% call rate, sex mismatches (between self-reported and genotypic 
predicted sex), low concordance with previous genotype data, duplicate samples, 
unanticipated genotype concordance, identity-by-descent with another sample or ethnic 
outliers as identified by visual inspection of PCA cluster plots were removed. Before 
imputation, SNPs with <95% call rate, concordance <95% with 1,000 Genomes in samples 
genotyped for QC, or Hardy-Weinberg equilibrium P<10−4 in controls were excluded. All 
SNPs overlapping 1,000 Genomes were matched to the forward strand.
The GECCO consortium consists of 13 studies. Details are provided in Supplementary 
Methods and Supplementary Table 1. In brief, DNA was extracted from blood samples or 
from buccal cells, using conventional methods. Phase one genotyping was done using either 
Illumina HumanHap 550K, 610K or combined Illumina 300K and 240K, Affymetrix 
platforms18, Illumina HumanCytoSNP or Illumina HumanOmniExpress. All studies 
included 1 to 6% blinded duplicates to monitor quality of the genotyping. All individual-
level genotype data were managed and underwent QA/QC at the Ontario Institute for Cancer 
Research, the University of Washington or at the Fred Hutchinson Cancer Research Center. 
Details on the QA/QC have previously been described12. In brief, samples were excluded 
based on call rate, heterozygosity, unexpected duplicates, gender discrepancy and 
unexpectedly high identity-by-descent or unexpected genotype concordance (>65%) with 
another individual. All analyses were restricted to samples clustering with the Utah residents 
with Northern and Western European ancestry from the CEPH collection (CEU) population 
in PC analysis, including the HapMap II populations as reference. SNPs were excluded if 
they were triallelic, not assigned an rs number, or were reported or observed as not 
performing consistently across platforms. In addition, genotyped SNPs were excluded based 
on call rate (< 98%), lack of Hardy-Weinberg equilibrium in controls (P<1×10−4) and minor 
allele frequency (MAF) (<5% in Set 1 for PLCO, WHI, DALS and OFCCR; minor allele 
count <10 for remaining studies).
Imputation
To meta-analyze genotype data generated from multiple platforms and to increase the 
coverage of variation that is measurable across the genome, imputation of genotypes was 
performed for both autosomal (all consortia) and X chromosome (excluding GECCO 
consortium) markers. Imputing missing genotypes for study samples based on the 
cosmopolitan panel of reference haplotypes from Phase I of the 1,000 Genomes Project 
(March 2012 release; n=1,092; (ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/release/
20110521))23,24 helps improve imputation accuracy of low-frequency variants38. The target 
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panel was phased using Beagle39 (GECCO) or SHAPE-IT40 (CORECT, MECC1 and CFR1) 
and the phased target panel was imputed to the 1,000 Genomes reference panel using either 
Minimac41 (GECCO) or IMPUTE242 (CORECT, MECC1 and CFR1). Genetic markers 
retained following imputation had to pass stringent imputation quality and accuracy filters 
before entering the analysis phase. For GECCO, Rsq was used as the imputation quality 
measure for imputed SNPs43, and SNPs were excluded at different Rsq thresholds based on 
their MAF; for SNPs with MAF>0.01, we excluded those with Rsq≤0.3; for MAFs of 
0.005–0.01, we excluded Rsq<0.5; and for MAF<0.005, we excluded Rsq<0.99. In the 
remaining studies (CORECT, MECC1 and CFR1) stringent imputation quality and accuracy 
filters (info≥0.7, certainty≥0.9, concordance≥0.9) were applied between directly measured 
and imputed genotypes after masking input genotypes (for genotyped markers only) to enter 
the analysis phase. Further, we restricted the SNP list to those with study-specific MAF≥1%.
Statistical analysis
We utilized PC analysis to assess correspondence between self-reported and genotypic 
classification of ancestry including unrelated HapMap CEU, YRI and ASN samples as 
population controls. Ancestral outliers were identified by visual inspection of PC plots for 
each study and removed. PCs were computed and used for ancestry adjustment. Study-
specific association estimates (OR and 95% CI) were obtained employing logistic regression 
of CRC on allelic dosage adjusting for ancestry and potential confounding variables (for 
example, age, sex and study site) as defined by the individual studies (Supplementary 
Methods). The genomic control factor (λ) was estimated by dividing the median X2-statistic 
by 0.456. A sample size-corrected marginal λ, equivalent to studying 1,000 cases and 1,000 
controls, was also calculated. Heterogeneity of genetic effects by study was assessed using 
Cochran’s Q test for heterogeneity (Phet).
Replication phase
The replication phase was conducted in two Asian consortia (Asian 1 and Asian 2). The 
Asian Colorectal Cancer Consortium (ACC), Asian 1, consisted of five studies with genome-
wide scan data: Shanghai CRC study 1 (Shanghai-1); Shanghai CRC Study 2 (Shanghai-2); 
Guangzhou CRC Study (Guangzhou); Aichi CRC Study 1 (Aichi-1), and the Korean Cancer 
Prevention Study-II CRC (KCPS-II). Samples in these studies were genotyped using 
Affymetrix and Illumina SNP arrays for GWAS (Supplementary Methods)10,44–48. A 
uniform QC protocol (call rates, concordance rates, cryptic relatedness, sex misidentification 
and ancestry) to filter samples and SNPs was applied10. Imputation was performed with the 
GIANT ALL data panel from the 1,000 Genomes Project phase1 release v3 as the reference 
using program MACH v1.043 and minimac41. SNPs with imputation r2>0.7 in each of the 
five studies were included in the final analysis. Associations between SNPs and CRC risk 
were evaluated based on the log-additive model using mach2dat43. Per-allele ORs and 95% 
confidence intervals (CIs) were derived from logistic regression models, adjusting for age, 
sex and the first ten PCs when appropriate. Association analysis was conducted for each 
participating study separately and a fixed-effects meta-analysis was conducted to obtain 
summary results with the inverse-variance method using program METAL49.
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The Asian 2 consortium was genotyped using the Illumina 1M-duo Array and consisted of 
studies from the Multiethnic Cohort (MEC; N=3,094), CFR (N=285), Colorectal cancer 
study on Oahu, Hawaii (CR2&3; N=134), Fukuoka, Japan (N=1,411), Nagano, Japan 
(N=207) and the Japan Public Health Center-based prospective study (JPHC; N=1,293) after 
QC filtering50–54. In general, all genotyped samples were examined and excluded according 
to the following: (1) call rates <90, 95 or 97% depending on the batches, (2) missing on 
basic covariates (age, sex or disease status), (3) gender mismatch, (4) ethnicity outliers and 
(5) relatedness (≥2nd degree). Prediction of untyped or partly genotyped SNPs was 
performed with BEAGLE 3.339 using the 1,000 Genomes Project (phase 1, release 3) East 
Asians as reference panels. Imputation was performed with all cases and controls combined. 
Markers with MAF<0.005 in reference panels were excluded from imputation. Study-
specific association statistics were obtained using logistic regression models adjusted for 
ancestry and potential confounding variables (Supplementary Methods). A fixed-effects 
meta-analysis was conducted to obtain summary results with the inverse-variance method 
using program METAL49.
All study samples were collected with written informed consent, and procedures were 
approved by the Human Research institutional review boards (IRBs) of the respective 
institutions. Specifically, the University of Southern California Health Sciences IRB 
approved all elements of the CORECT, CFR and MECC studies. The MECC study protocol 
was also approved by the IRBs at the University of Southern California, University of 
Michigan, and Carmel Medical Center (Haifa). The Fred Hutchinson Cancer Research 
Center IRB approved the GECCO contribution. The Asian 1 consortia study protocols were 
approved by the review board of the Vanderbilt University Medical Center and informed 
consent was obtained from all study participants. Study protocols of the Asian 2 consortia 
were approved by the University of Hawaii Human Studies Program and University of 
Southern California IRB, the IRB in the National Cancer Center, Japan and the Ethics 
Committee of Kyushu University Faculty of Medical Sciences.
Meta-analysis
A consortia-wide meta-analysis for the discovery and replication phases using fixed-effect 
models with inverse variance weighting was implemented in METAL. Heterogeneity was 
evaluated using Cochran’s Q test for heterogeneity and the measure I2. Graphical 
representation of effect estimates and CIs by study and consortia are presented using forest 
plots.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Forest plots summarizing ORs from studies contributing to colorectal cancer meta-
analysis identifying six loci reaching genome-wide significance
The P value from the Cochran’s Q test for heterogeneity (Phet) is presented by SNP. ** 
indicates a subset of the study ARCTIC; *** indicates colorectal polyps. The study specific 
ORs (blue rectangles) and 95% confidence intervals (CI; horizontal bars) are plotted for each 
SNP. The red diamonds represent the summary OR and 95% CI for the ‘Discovery’ series (N 
= 18,299 cases/19,656 controls) and ‘Overall’. The ‘Replication’ series included the Asian 1 
(N = 2,098 cases/6,172 controls) and Asian 2 (N = 2,627 cases/3,797 controls) consortia.
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